Emergent BioSolutions (EBS) Assets (2010 - 2026)

Emergent BioSolutions has reported Assets for 17 years, with the latest figure at $1.1 billion in Q2 2026.

• On a quarterly basis, Assets fell 21.19% year-over-year to $1.1 billion in Q2 2026; TTM through Jun 2026 was $1.1 billion, a 21.19% decrease from a year earlier, with the FY2025 full-year figure at $1.3 billion, down 5.12% from the prior year.
• Assets was $1.1 billion for Q2 2026 at Emergent BioSolutions, down from $1.3 billion in the prior quarter.
• The five-year high for Assets was $3.2 billion in Q4 2022, with the low at $1.1 billion in Q2 2026.
• Average Assets over 5 years is $1.9 billion, with a median of $1.7 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Assets climbed 7.05% in 2022, then sank 42.42% in 2023.
• Over 5 years, Assets stood at $3.2 billion in 2022, then tumbled by 42.42% to $1.8 billion in 2023, then retreated by 23.78% to $1.4 billion in 2024, then fell by 5.12% to $1.3 billion in 2025, then fell by 15.3% to $1.1 billion in 2026.
• The last three Assets figures came in at $1.1 billion (Q2 2026), $1.3 billion (Q1 2026), and $1.3 billion (Q4 2025), per Business Quant data.